maXis II is THE market leading high-resolution LC-QTOF, leading the way in QTOF technology with unprecedented performance across wide ranging applications, to resolve the most demanding analytical challenges.
A full range of specified performance parameters is delivered simultaneously.
Bruker's Ultra-High Resolution QTOF (UHR) technology has reached new standards
in accurate-mass LC-MS/MS. In addition, the system offers Electron-Transfer Dissociation (ETD) capabilities for sequence analysis of intact proteins including monoclonal antibody subunits.
Furthermore, native state samples, including antibody drug conjugates, can be measured at these enhanced performance levels (Native Mass Spectrometry).
Antibody Characterization - Intact and Subunit Analysis
Enhanced resolution and mass precision - for highly precise and accurate determinations of the monoisotopic masses of both the Light and Heavy Chains of mAb's on an LC timescale for automated confirmation of product identity and detection of impurities. Superb raw data quality allows for fast and easy detection of modifications (including deamidation) in biotherapeutic characterization without the need for time and cost intensive digestion and peptide mapping of the entire antibody.
Native Mass Spectrometry (optional)
The High Mass Option combines adjustable Funnel 1 pressure with in-source CID on the maXis II to permit efficient desolvation and ionization of the native sprayed analyte without sacrificing other performance vectors. Thereby enabling easier application of native MS or high mass workflows for the structural investigation of larger proteins and/or protein complexes (including antibody drug conjugates)
Complex Protein Mixture
The maXis II delivers superb dynamic range (5 orders of magnitude) at UPLC speeds enabling analysis of protein mixtures in complex, high-background matrices. For example > 1000 proteoforms resolved in a 35 min run from an undiluted serum sample.
Robust LC-ETD capabilities
(with novel nCI source and Gas Enrichment Apparatus (optional)). Top-down MW measurement plus LC-ETD sequence data for rapid detection and localizion of post-translational modifications (PTMs) in mAb's
For Research Use Only. Not for use in clinical diagnostic procedures.